These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17037261)

  • 1. Sequential designs for logistic phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential designs for ordinal phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    Biom J; 2009 Apr; 51(2):335-47. PubMed ID: 19358220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of sequential dose-finding designs.
    O'Quigley J
    Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-stage dose selection strategy in phase I trials with wide dose ranges.
    Wang O; Faries DE
    J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
    Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
    Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dose-finding designs with correlated continuous and discrete responses.
    Fedorov V; Wu Y; Zhang R
    Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.